NASDAQ:APRE Aprea Therapeutics Q4 2024 Earnings Report $1.77 -0.01 (-0.69%) Closing price 06/18/2025 03:57 PM EasternExtended Trading$1.82 +0.06 (+3.24%) As of 06/18/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Aprea Therapeutics EPS ResultsActual EPS-$0.49Consensus EPS -$0.69Beat/MissBeat by +$0.20One Year Ago EPSN/AAprea Therapeutics Revenue ResultsActual Revenue$0.21 millionExpected Revenue$0.15 millionBeat/MissBeat by +$56.00 thousandYoY Revenue GrowthN/AAprea Therapeutics Announcement DetailsQuarterQ4 2024Date3/25/2025TimeBefore Market OpensConference Call DateTuesday, March 25, 2025Conference Call Time8:00AM ETUpcoming EarningsAprea Therapeutics' Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesSlide DeckPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Aprea Therapeutics Earnings HeadlinesShort Interest in Aprea Therapeutics, Inc. (NASDAQ:APRE) Grows By 24.9%June 20 at 3:52 AM | americanbankingnews.comAprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical UpdateMay 14, 2025 | globenewswire.comThe IRS Loophole That Lets You Own Gold Tax-FreeWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? No gimmicks. No shady tricks. Just a powerful IRS-approved loophole that most Americans have never heard of. It's called a Self-Directed Gold IRA, and it's quietly becoming the go-to wealth protection strategy for people who see the writing on the wall. When you take the next step, you could qualify for up to $10,000 in FREE GOLD & SILVER with your purchase of a qualified account.June 20, 2025 | Advantage Gold (Ad)Halda Therapeutics Announces Appointment of Eyal Attar, MD, as Chief Medical OfficerApril 23, 2025 | finance.yahoo.comAprea Therapeutics Doses First Patient With HPV+ HNSCC In ACESOT-1051 TrialApril 2, 2025 | nasdaq.comAprea Therapeutics Advances ACESOT-1051 Clinical Trial with Key Patient DosingApril 2, 2025 | msn.comSee More Aprea Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aprea Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aprea Therapeutics and other key companies, straight to your email. Email Address About Aprea TherapeuticsAprea Therapeutics (NASDAQ:APRE), a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.View Aprea Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Broadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Aheade.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Upcoming Earnings FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025)Bank of America (7/14/2025)Wells Fargo & Company (7/14/2025)JPMorgan Chase & Co. (7/14/2025)Interactive Brokers Group (7/15/2025)America Movil (7/15/2025)Citigroup (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
